Details
June 7 @ 3:00 pm – 3:45 pm CDT
Product Theater 2
Supported By: Corcept Therapeutics
Program Description
Join our expert panel to explore the latest evidence, understand evolving perspectives, and examine clinical implications of hypercortisolism to inform better patient care.
This program is not part of the 2026 Scientific Sessions as planned by the American Diabetes Association® (ADA). This event is neither sponsored nor endorsed by the ADA. This event does not qualify for continuing medical education (CME) credit.
Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.
Speakers
Panelist
Pamela R. Kushner MD, FAAFP
Clinical Professor of Family Medicine
University of California, Irvine College of Medicine
Irvine, CA
Panelist
John Anderson MD
Private Practice
The Frist Clinic
Internal Medicine and Diabetes
Nashville, TN
Panelist
Honey East MD, FACP
Director
Metabolic Medicine of Mississippi
Jackson, MS